'FDA Grants Priority Review Of MDMA-Assisted Therapy For PTSD, Psychedelics Drug Development Company Says' - Marijuana Moment
'FDA Grants Priority Review Of MDMA-Assisted Therapy For PTSD, Psychedelics Drug Development Company Says' - Marijuana Moment
“迷幻药药物开发公司表示，美国食品药品管理局批准对创伤后应激障碍的摇头丸辅助疗法进行优先审查”-大麻时刻
The Food and Drug Administration (FDA) has agreed to review MDMA-assisted therapy as a potential treatment option for post-traumatic stress disorder (PTSD), and the application has been granted priority status, according to the psychedelics-focused drug development company that's leading the effort.
领导这项工作的专注于迷幻药的药物开发公司表示，美国食品药品监督管理局（FDA）已同意审查摇头丸辅助疗法作为创伤后应激障碍（PTSD）的潜在治疗选择，该申请已获得优先地位。
About two months after Lykos Therapeutics (formerly MAPS Public Benefit Corporation) submitted the new drug application (NDA) for MDMA in combination with psychotherapy, FDA granted it priority review last week and has set a target date for determination by August 11, the company announced on Friday.
该公司周五宣布，在Lykos Therapeutics（前身为MAPS公共福利公司）提交结合心理治疗的摇头丸新药申请（NDA）大约两个月后，美国食品药品管理局上周批准了其优先审查，并将确定目标日期定为8月11日。
If the NDA is ultimately approved, the Drug Enforcement Administration...
如果保密协议最终获得...
登录免费看全文
登录/注册